Neil Solomons - Nov 1, 2021 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)

Role
Chief Medical Officer
Signature
/s/ Neil Solomons, M.D.
Stock symbol
AUPH
Transactions as of
Nov 1, 2021
Transactions value $
-$1,185,300
Form type
4
Date filed
11/3/2021, 04:24 PM
Previous filing
Sep 14, 2021
Next filing
Nov 12, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AUPH Common Stock Options Exercise $239K +45K +32.78% $5.30 182K Nov 1, 2021 Direct F1
transaction AUPH Common Stock Sale -$1.42M -45K -24.68% $31.64 137K Nov 1, 2021 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AUPH Stock Option (right to buy) Options Exercise $0 -45K -25.71% $0.00 130K Nov 1, 2021 Common Stock 45K $5.30 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3 The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $31.50 to $31.74, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F4 The shares subject to the option vest in thirty-six equal monthly installments from the grant date.